Company

Unity Biotechnology, Inc.

Headquarters: South San Francisco, CA, United States

Founded: 2011

Employees: 66

CEO: Dr. Anirvan Ghosh

NASDAQ: UBX +0.68%

Market Cap

$31.6 Million

USD as of Jan. 1, 2024

Market Cap History

Unity Biotechnology, Inc. market capitalization over time

Evolution of Unity Biotechnology, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Unity Biotechnology, Inc.

Detailed Description

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Unity Biotechnology, Inc. has the following listings and related stock indices.


Stock: NASDAQ: UBX wb_incandescent

Stock: FSX: 9U9 wb_incandescent

Key People

Founder(s): Judith Campisi, Jan van Deursen, Nathaniel “ Ned” David, Daohong Zhou

Details

Headquarters:

285 East Grand Avenue

South San Francisco, CA 94080

United States

Phone: 650 416 1192